A Phase 2 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Neoplasms and Cancer of the Ovary, sponsored by Sanofi. Completed at 11 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Ovarian Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Ovarian Neoplasms · Sanofi.
Among the 14 studies in Ovarian Neoplasms by Sanofi, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2006, is one of 9 in phase 2, and was the 3rd registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 14 studies in Ovarian Neoplasms by Sanofi is open now. The open studies under Ovarian Neoplasms, anywhere →
Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 1
First in 1999; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 13 interventional studies, 30 across the 1 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Ovarian Neoplasms by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated outcomes in participants with advanced ovarian epithelial adenocarcinoma receiving aflibercept.
The primary objective was to compare the objective response rate of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) 4.0 mg/kg and 2.0 mg/kg, administered intravenously (IV) every 2 weeks with historical control in participants with advanced ovarian epithelial (including fallopian tube and primary peritoneal) adenocarcinoma resistant to platinum and topotecan and/or liposomal doxorubicin.
The secondary objectives was to further assess efficacy, safety, pharmacokinetics, potential biological and pharmacogenomic markers of study drug activity, and health-related quality of life.
This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation. If an endpoint was evaluated by the IRC, the IRC reviewed data is reported for this study.
The study included:
Withdrawal criteria that led to treatment discontinuation were:
After discontinuing treatment, participants remained on the study until the last post-treatment visit or until recovery of drug related toxicities, whichever was later.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
This study's enrollment of 218 is above the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.
Browse Ovarian Neoplasms studies →Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Compared within Ovarian Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who met the following criteria were eligible for the study.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks. Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks. Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort
OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population
OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Number of Participants With a Clinical Benefit Response (CBR) as Per RECIST Based on the Analysis by the IRC
CBR was defined as having a Stable disease (SD) for \>= 6 months or a confirmed OR (PR or CR). Based on RECIST: * SD was neither a sufficient shrinkage of the target lesions to qualify for PR nor sufficient increase to qualify for Progressive disease (PD), the persistence of non-target lesions or the maintenance of tumor marker level above the normal limits (for non-target lesions) * CR was the disappearance of all target or non-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Duration of Response (DR) Based on the Analysis by an Independent Review Committee (IRC)
DR was defined as the time interval from the first documentation of CR or PR to the date of tumor progression (or disease progression) as determined by RECIST, or death from any cause, whichever was earlier. Based on RECIST, progressive disease was at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, the appearance of one or more new target or non-target lesions, or the unequivocal progression of existing non-target lesions.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Tumor Marker Response Rate (TMRR) Based on the Gynecologic Cancer Intergroup (GCIG) Definition
TMRR was the proportion of evaluable participants achieving a cancer antigen -125 (CA-125) response based on GCIG definition. A response to CA-125 occurred if after two elevated levels before therapy there was at least a 50% decrease in a post-treatment serum sample, which was confirmed by an independent sample collected 21 days or later that was =\< 110% of the post-treatment serum sample.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Time to Tumor Progression (TTP) as Per RECIST Based on the Analysis by the IRC
TTP was defined as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST. TTP was estimated from Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Time to Tumor Marker (CA-125) Progression (TTMP)
TTMP was the time interval from the date of randomization to the date of tumor marker progression as was defined by GCIG for the evaluable participants. TTMP was estimated using Kaplan-Meier curves. For a participant who did not reach tumor marker progression (TMP) during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Number of Participants With Disease Progression Events for Progression-free Survival (PFS) Analysis by the IRC.
PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. The number of participants with tumor/disease progression are reported. Participants who did not reach tumor progression during study, or had no valid post-baseline tumor burden assessment due to early termination, were censored in the PFS analysis.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Progression-free Survival (PFS) Time Based on Analysis by the IRC
PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. PFS was estimated using Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Overall Survival (OS) Time
OS was the time interval between randomization and the date of death from any cause. OS was estimated using Kaplan-Meier curves A participant was censored for the OS analysis if the participant were alive during the study. The censoring date was either at the date that the participant was last known to be alive or the date of study cut-off, whichever was earlier.
Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Overall Safety - Number of Participants With Adverse Events (AE)
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
Time frame: up to 30+/-5 days after treatment discontinuation, or up to recovery or stabilization of a followed-up adverse event
Participant's Assessment of Health Related Quality of Life (HRQL) Using a by Using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Questionnaire
The FACT-O questionnaire consists of 38 scored questions (scored from 0-4) that address physical well-being, social/family well-being, emotional well-being, functional well-being and some additional concerns which relate specifically to ovarian cancer symptoms. For each question, higher scores reflect a better quality of life. The total FACT-O score ranges from 0-152, with 152 indicating the best outcome.
Time frame: On Day 1 of Cycle 1 (baseline) , and after Day 14 of Cycle 2
218 participants were randomized in this study. Three participants in the 2 mg/kg treatment group did not receive any study medication.
| Milestone | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Started | 109 | 109 |
| Completed | 1 | 0 |
| Not completed | 108 | 109 |
| Withdrew: Did not receive study medication | 3 | 0 |
| Withdrew: Adverse event | 23 | 23 |
| Withdrew: Disease progression/lack of efficacy | 68 | 69 |
| Withdrew: Investigator/participant request | 1 | 8 |
| Withdrew: Clinical progression | 12 | 8 |
| Withdrew: Undisclosed history of ischemia | 0 | 1 |
| Withdrew: Other | 1 | 0 |
OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.
| participants | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort | 0 | 3 |
CBR was defined as having a Stable disease (SD) for \>= 6 months or a confirmed OR (PR or CR). Based on RECIST: * SD was neither a sufficient shrinkage of the target lesions to qualify for PR nor sufficient increase to qualify for Progressive disease (PD), the persistence of non-target lesions or the maintenance of tumor marker level above the normal limits (for non-target lesions) * CR was the disappearance of all target or non-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD.
| participants | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Number of Participants With a Clinical Benefit Response (CBR) as Per RECIST Based on the Analysis by the IRC | 12 | 7 |
DR was defined as the time interval from the first documentation of CR or PR to the date of tumor progression (or disease progression) as determined by RECIST, or death from any cause, whichever was earlier. Based on RECIST, progressive disease was at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, the appearance of one or more new target or non-target lesions, or the unequivocal progression of existing non-target lesions.
| days | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Duration of Response (DR) Based on the Analysis by an Independent Review Committee (IRC) | 164 ± NA | 149.8 ± 70.4 |
TMRR was the proportion of evaluable participants achieving a cancer antigen -125 (CA-125) response based on GCIG definition. A response to CA-125 occurred if after two elevated levels before therapy there was at least a 50% decrease in a post-treatment serum sample, which was confirmed by an independent sample collected 21 days or later that was =\< 110% of the post-treatment serum sample.
| percentage of participants | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Tumor Marker Response Rate (TMRR) Based on the Gynecologic Cancer Intergroup (GCIG) Definition | 11.5 (4.7 to 22.2) | 11.6 (5.1 to 21.6) |
TTP was defined as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST. TTP was estimated from Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.
| weeks | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Time to Tumor Progression (TTP) as Per RECIST Based on the Analysis by the IRC | 13.1 (12.1 to 16.7) | 12.7 (12 to 18.9) |
TTMP was the time interval from the date of randomization to the date of tumor marker progression as was defined by GCIG for the evaluable participants. TTMP was estimated using Kaplan-Meier curves. For a participant who did not reach tumor marker progression (TMP) during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.
| weeks | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Time to Tumor Marker (CA-125) Progression (TTMP) | NA (24.1 to NA) | NA (22.7 to NA) |
PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. The number of participants with tumor/disease progression are reported. Participants who did not reach tumor progression during study, or had no valid post-baseline tumor burden assessment due to early termination, were censored in the PFS analysis.
| participants | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| With disease progression as the first event | 66 | 66 |
| Death without disease progression | 16 | 23 |
| Censored due to drop-out | 18 | 14 |
| Censored at study cut-off | 6 | 6 |
PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. PFS was estimated using Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.
| weeks | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Progression-free Survival (PFS) Time Based on Analysis by the IRC | 13.0 (11.7 to 16.7) | 13.3 (11.2 to 18.9) |
OS was the time interval between randomization and the date of death from any cause. OS was estimated using Kaplan-Meier curves A participant was censored for the OS analysis if the participant were alive during the study. The censoring date was either at the date that the participant was last known to be alive or the date of study cut-off, whichever was earlier.
| weeks | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Overall Survival (OS) Time | 59.0 (41.6 to 84.1) | 49.3 (37.4 to 62.7) |
OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.
| participants | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population | 1 | 5 |
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
| participants | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| With any TEAE | 106 | 108 |
| With any serious TEAE | 50 | 55 |
| With any TEAE leading to death | 14 | 14 |
| With TEAE leading to treatment discontinuation | 23 | 24 |
The FACT-O questionnaire consists of 38 scored questions (scored from 0-4) that address physical well-being, social/family well-being, emotional well-being, functional well-being and some additional concerns which relate specifically to ovarian cancer symptoms. For each question, higher scores reflect a better quality of life. The total FACT-O score ranges from 0-152, with 152 indicating the best outcome.
| score on a scale | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Baseline (N=97, N=104) | 105.3 ± 20.0 | 101.1 ± 22 |
| Change (baseline to Cycle 2-Day 14) (N=79, N=77) | -1.1 ± 12.7 | -2.8 ± 13.9 |
Collected over From treatment initiation to June 9, 2010. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aflibercept 2.0 mg/kg | — | 51/106 (48.1%) | 105/106 (99.1%) |
| Aflibercept 4.0 mg/kg | — | 56/109 (51.4%) | 106/109 (97.2%) |
| Event | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 10/106 | 6/109 |
| Disease progressionGeneral disorders | 3/106 | 7/109 |
| Abdominal painGastrointestinal disorders | 4/106 | 6/109 |
| HypertensionVascular disorders | 4/106 | 6/109 |
| DehydrationMetabolism and nutrition disorders | 4/106 | 2/109 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/106 | 4/109 |
| NauseaGastrointestinal disorders | 3/106 | 0/109 |
| Renal failureRenal and urinary disorders | 3/106 | 3/109 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/106 | 1/109 |
| AnaemiaBlood and lymphatic system disorders | 2/106 | 1/109 |
| Event | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg |
|---|---|---|
| HypertensionVascular disorders | 60/106 | 57/109 |
| HeadacheNervous system disorders | 54/106 | 54/109 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 39/106 | 46/109 |
| NauseaGastrointestinal disorders | 44/106 | 43/109 |
| FatigueGeneral disorders | 42/106 | 44/109 |
| Decreased appetiteMetabolism and nutrition disorders | 42/106 | 30/109 |
| Abdominal painGastrointestinal disorders | 36/106 | 40/109 |
| VomitingGastrointestinal disorders | 38/106 | 30/109 |
| DiarrhoeaGastrointestinal disorders | 31/106 | 39/109 |
| ConstipationGastrointestinal disorders | 37/106 | 27/109 |
| Age, Customized(participants) | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg | Total |
|---|---|---|---|
| <35 years | 3 | 3 | 6 |
| >=35 to <45 years | 10 | 6 | 16 |
| >=45 to <55 years | 21 | 25 | 46 |
| >=55 to <65 years | 37 | 43 | 80 |
| >=65 to <75 years | 32 | 25 | 57 |
| >=75 years | 6 | 7 | 13 |
| Sex: Female, Male(Participants) | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg | Total |
|---|---|---|---|
| Female | 109 | 109 | 218 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Aflibercept 2.0 mg/kg | Aflibercept 4.0 mg/kg | Total |
|---|---|---|---|
| Caucasian | 104 | 107 | 211 |
| Black | 3 | 1 | 4 |
| Asian, Oriental | 1 | 1 | 2 |
| Unknown or Not Reported | 1 | 0 | 1 |
The record gives a start of May 2006, a primary completion of Apr 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 4 years 6 months after primary completion. A results delay was requested in Aug 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept